A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.
A new cervical cancer treatment is showing promise in boosting survival rates and reducing recurrence What this breakthrough means for patients.
Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback